Results 201 to 210 of about 627,005 (317)
Epidemiology of Dry Eye in Patients With Autoimmune Disease.
Chen NN, Huang YT, Sun CC.
europepmc +1 more source
CAR-T cell therapy: A new dawn in the treatment of autoimmune disease. [PDF]
Yan S, Zhu X, Xiao Y.
europepmc +1 more source
Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?
Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet +11 more
wiley +1 more source
Köbner Phenomenon in a Rituximab-Treated Pemphigus Patient: Beware Disease Activity
Soheil Tavakolpour +4 more
doaj +1 more source
Th17 cell pathogenicity in autoimmune disease. [PDF]
Park E, Ciofani M.
europepmc +1 more source
Thioketal (TK) polymers are promising biomaterials due to their selective biodegradation by reactive oxygen species (ROS), but they respond slowly to physiologic doses of ROS. Here, the TK bond's pendant groups are modified to enhance the degradation of TK‐based implants both in vitro and in vivo.
Karina A. Bruce +6 more
wiley +1 more source
Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease. [PDF]
Bracken SJ, St Clair EW.
europepmc +1 more source
Decellularized Extracellular Matrix (dECM) in Tendon Regeneration: A Comprehensive Review
Decellularized Extracellular Matrix (dECM) offers a promising solution by replicating the native tendon microenvironment and promoting regeneration. This review highlights advances in the decellularization methods, as well as their integration with emerging technologies and translational progress in tendon tissue engineering.
Kumaresan Sakthiabirami +4 more
wiley +1 more source
Clinical characterization and targeted genetic mutation profiling of autoimmune disease-associated B-cell lymphoma. [PDF]
Di H +7 more
europepmc +1 more source
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan +13 more
wiley +1 more source

